FGFR2 and intrahepatic cholangiocarcinoma: Futibatinib, an irreversible FGFR1-4 inhibitor, has also demonstrated efficacy among previously treated patients with intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements in the FOENIX-CCA2 (NCT02052778) pivotal phase 2 trial [23].